恒宇信通航空装备（北京）股份有限公司发布重大资产重组及股票复牌公告
一、公告要点
- 交易方式与标的： 恒宇信通航空装备（北京）股份有限公司（以下简称“公司”）拟通过发行股份及支付现金的方式，收购张俊清等9名交易对方持有的北京神导科技股份有限公司（简称“神导科技”）全部（100%）股权。
- 配套融资： 公司计划向不超过35名符合条件的特定投资者发行股份，募集配套资金，用于本次交易。
- 交易性质： 本次交易预计构成重大资产重组和关联交易，但不构成重组上市，也不会导致公司实际控制人变更。
- 股票停复牌安排： 公司股票自2026年4月27日开市起停牌，预计停牌不超过10个交易日。经董事会审议通过相关议案后，将于2026年5月13日开市起复牌。
- 后续流程与不确定性： 该交易需完成审计、评估后提交董事会和股东大会审议，并需深圳证券交易所审核与中国证监会同意注册，最终能否获批及时间尚不确定。
二、对股东和投资者的重要影响
- 潜在股价影响： 本次收购神导科技全部股权及配套融资计划属于重大资产重组事项，有可能对公司资产规模、业务范围、盈利能力等产生重大影响，进而影响公司估值和股价表现。
- 关联交易风险： 由于涉及关联交易，投资者需关注交易价格公允性及可能存在的利益输送风险。
- 审批及不确定性风险： 交易尚需多重审批，存在审批不通过或进度延迟的风险，短期内可能带来股价波动。
- 信息披露： 公司承诺将严格履行信息披露义务，所有相关信息以法定信息披露媒体为准，提醒投资者理性投资、关注后续公告。
三、详细内容梳理
公司于2026年5月12日召开董事会，审议并通过了《关于恒宇信通航空装备（北京）股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案》及相关议案。公司股票将于2026年5月13日复牌，并将继续推进后续工作。待审计、评估完成后，公司将召开董事会及股东大会审议相关事项，并报送相关监管部门审核。
投资者需特别关注：
1. 本次交易涉及资产重组和关联交易，具有较强的不确定性；
2. 复牌后相关信息和进展可能对股价产生较大波动；
3. 相关交易能否顺利实施，仍取决于后续审批进展。
四、结语
本次公告内容为公司重大资产重组及股票复牌的进展说明，对公司未来发展和投资价值具有重要影响，投资者请密切关注后续公告，理性决策。
【免责声明】
本文仅为信息整理和分析，不构成投资建议。请投资者以公司在法定披露媒体发布的公告为准，注意投资风险。
English Version:
Hengyu Xintong Announces Major Asset Restructuring and Stock Resumption
Key Points
- Transaction and Target: Hengyu Xintong Aviation Equipment (Beijing) Co., Ltd. (the “Company”) plans to acquire 100% equity of Beijing Shendao Technology Co., Ltd. (“Shendao Technology”) held by Zhang Junqing and 8 other parties through a combination of share issuance and cash payment.
- Supporting Fundraising: The Company also plans to issue shares to no more than 35 qualified specific investors to raise supporting funds for the transaction.
- Nature of Transaction: This transaction is expected to constitute a major asset restructuring and a related-party transaction, but will not constitute a backdoor listing and will not result in a change of the actual controller of the company.
- Trading Suspension & Resumption: The company’s shares were suspended from April 27, 2026, for up to 10 trading days. Following board approval, trading will resume from May 13, 2026.
- Subsequent Process & Uncertainty: The transaction must complete audit and appraisal steps, then be reviewed by the board and shareholders’ meeting, and is subject to approval by the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission. There is uncertainty regarding approval and timing.
Potential Impact on Shareholders & Investors
- Potential Price Impact: The acquisition and related fundraising represent a significant asset restructuring, which may materially affect asset scale, business scope, and profitability, and thus impact valuation and share price.
- Related-Party Transaction Risk: As the transaction involves related parties, investors should pay attention to the fairness of the transaction price and the risk of possible interest transfers.
- Approval and Uncertainty Risk: Multiple approvals are required, and there is a risk of delay or disapproval, which may cause short-term share price volatility.
- Information Disclosure: The company will strictly comply with disclosure obligations; all information is subject to official disclosures. Investors are urged to stay rational and follow further updates.
Detailed Summary
On May 12, 2026, the board approved the preliminary plan for this transaction. Shares will resume trading on May 13, 2026, and the company will proceed with subsequent steps. After audit and appraisal, the board and shareholders’ meeting will review the transaction, with final approval required by the regulators.
Investors should focus on:
1. The transaction involves major restructuring and related-party dealings, with inherent uncertainty;
2. Developments post-resumption may cause significant share price movement;
3. Execution depends on subsequent regulatory approvals.
Conclusion
This announcement details a major asset restructuring and stock resumption, which may have a significant impact on the company’s future development and investment value. Investors should follow further official announcements and make rational decisions.
[Disclaimer]
This article is for information collation and analysis only and does not constitute investment advice. Please refer to the company’s official disclosures for authoritative information and note investment risks.
